CellCentric
A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
About
Technology stack
detected 2026-06-14No comments yet. Be the first to share your take.
What does CellCentric do?
CellCentric is a clinical-stage biotechnology company focused on developing inobrodib, a novel oral p300/CBP inhibitor, for the treatment of multiple myeloma. The company recently completed an oversubscribed $220 million Series D financing round, which will be used to advance the development of inobrodib.
How much funding has CellCentric raised?
CellCentric has raised a total of $375M in funding. The most recent round on record is Series D.
Where is CellCentric headquartered?
CellCentric is headquartered in Cambridge, England, United Kingdom.
When was CellCentric founded?
CellCentric was founded in 2003.
What industry does CellCentric operate in?
CellCentric operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Medical, Therapeutics.
How many employees does CellCentric have?
CellCentric has approximately 53 people on record.